Bioinformatics analysis of the diagnostic significance and functions of RDH5 in breast cancer

Objective: RDH5 (Retinol dehydrogenase 5) is one of the member of the short-chain dehydrogenase/reductase (SDR) family and plays a critical role in a variety of tumor processes. In this study, we analyzed the expression, diagnostic significance and gene function of RDH5 in breast cancer. Methods: The Gene Expression Profiling Interactive Analysis (GEPIA) database was used to determine the diagnostic and prognostic value of RDH5 and the University of Alabama at Birmingham (UALCAN) database analyzed its expression in different subtypes, clinical stages and altered signal pathways in breast cancer. Then we explored the co-expression gene of RDH5 in breast cancer and constructed its corresponding network through the cBioPortal database. The String database was used to determine its interactions with other proteins. Results: RDH5 expression was differentiated in various tumours compared to normal tissue, and was down-regulated in breast cancer tissue and different subtypes of breast cancer. There was no correlation between RDH5 and the survival of breast cancer. RDH5 expression was significantly associated with different clinical parameters. Additionally, the protein expression of RDH5 in breast cancer with altered pathways indicated it was closely associated with the SWI-SNF (switching/sucrose non-fermenting) complex status and the mammalian Target of Rapamycin (mTOR), WNT (Wingless/Integrated), MYC/MYCN (Myelocytomatosis oncogene/euroblastoma derived MYC), RTK (receptor Tyrosine kinases), and p53/Rb (tumor protein p53/Retinoblastoma) pathways. Interaction analysis with RDH5 and its co-expression genes showed that its main related functions were ethanol oxidation, regulation of heart contraction and negative regulation of tumor necrosis factor. Lastly, the Protein-protein interaction (PPI) of RDH5 showed that the most relevant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were retinol metabolism, vitamin digestion and absorption and metabolic pathways. Conclusion: These results implied that RDH5 might be a larvaceous diagnostic biomarker for breast cancer and was closely associated with its metabolism. However, more studies are needed to confirm our findings and support the clinical importance of RDH5 in breast cancer.

RDH5; Breast cancer; Co-expression network; Metabolism

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Yan Y, Zhou Y, Wang K, Qiao Y, Zhao L, Chen M. Apolipoprotein C1 (APOC1), a candidate diagnostic serum biomarker for breast cancer identified by serum proteomics study. Critical Reviews in Eukaryotic Gene Expression. 2022; 32: 1–9.

[3] Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P. Breast cancer statistics and markers. Journal of Cancer Research and Therapeutics. 2014; 10: 506–511.

[4] Skorczyk-Werner A, Pawłowski P, Michalczuk M, Warowicka A, Wawrocka A, Wicher K, et al. Fundus albipunctatus: review of the literature and report of a novel RDH5 gene mutation affecting the invariant tyrosine (p.Tyr175Phe). Journal of Applied Genetics. 2015; 56: 317–327.

[5] Liu X, Liu L, Li H, Xu F, Jiang R, Sui R. RDH5 retinopathy (fundus albipunctatus) with preserved rod function. Retina. 2015; 35: 582–589.

[6] Makiyama Y, Ooto S, Hangai M, Ogino K, Gotoh N, Oishi A, et al. Cone abnormalities in fundus albipunctatus associated with RDH5 mutations assessed using adaptive optics scanning laser ophthalmoscopy. American Journal of Ophthalmology. 2014; 157: 558–570.e4.

[7] Zhang M, Chen H, Wang M, Bai F, Wu K. Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer. Bioscience Reports. 2020; 40: BSR20193286.

[8] Jézéquel P, Frénel J. S, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G, et al. bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database: The Journal of Biological Databases and Curation. 2013; 2013: bas060.

[9] Chen W, Yang S, Xu W, Deng F, Wang D, Tang J. Bioinformatics analysis revealing prognostic significance of TIMP2 gene in breast cancer. Medicine. 2021; 100: e27489.

[10] Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling. 2013; 6: pl1.

[11] Milulescu A, Di Marino L, Peradze N, Toesca A. Management of multifocal-multicentric breast cancer: current perspective. Chirurgia. 2017; 112: 12.

[12] Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. Journal of Hematology & Oncology. 2019; 12: 71.

[13] Harwood FC, Klein Geltink RI, O’Hara BP, Cardone M, Janke L, Finkelstein D, et al. ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Science Advances. 2018; 4: eaar3938.

[14] Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017; 36: 1461–1473.

[15] Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Molecular Cancer. 2018; 17: 34.

[16] Zhang L, Liu M, Liu W, Hu C, Li H, Deng J, et al. Th17/IL-17 induces endothelial cell senescence via activation of NF-κB/p53/Rb signaling pathway. Laboratory Investigation. 2021; 101: 1418–1426.

[17] Kinoshita F, Kohashi K, Sugimoto M, Takamatsu D, Kiyozawa D, Eto M, et al. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features. Virchows Archiv. 2020; 477: 651–660.

[18] Nardin S, Mora E, Varughese FM, D’Avanzo F, Vachanaram AR, Rossi V, et al. Breast cancer survivorship, quality of life, and late toxicities. Frontiers in Oncology. 2020; 10: 864.

[19] Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 2017; 389: 1195–1205.

[20] Mayor S. Screening for early breast cancer reduces invasive cancer, study finds. BMJ. 2015; 351: h6576.

[21] Hamann M, Grill S, Struck J, Bergmann A, Hartmann O, Pölcher M, et al. Detection of early breast cancer beyond mammographic screening: a promising biomarker panel. Biomarkers in Medicine. 2019; 13: 1107–1117.

[22] Katagiri S, Hayashi T, Nakamura M, Mizobuchi K, Gekka T, Komori S, et al. RDH5-related fundus albipunctatus in a large japanese cohort. Investigative Ophthalmology & Visual Science. 2020; 61: 53.

[23] Kang G, Hwang WC, Do IG, Wang K, Kang SY, Lee J, et al. Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PLoS One. 2013; 8: e82770.

[24] Kropotova ES, Zinovieva OL, Zyryanova AF, Dybovaya VI, Prasolov VS, Beresten SF, et al. Altered expression of multiple genes involved in retinoic acid biosynthesis in human colorectal cancer. Pathology & Oncology Research. 2014; 20: 707–717.

[25] Beltrami CM, dos Reis MB, Barros-Filho MC, Marchi FA, Kuasne H, Pinto CAL, et al. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas. Clinical Epigenetics. 2017; 9: 45.